Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at KWTRP and University of Oxford collaborate to evaluate the ChAdOx1 nCOV-19 vaccine in Kenya

This video explains the collaboration between KWTRP and the University of Oxford to review the ChAdOx1 nCOV-19 vaccine and conduct phase I and II trials in Kenya.

Visit the Frequently Asked Questions page about the trial on the KWTRP website

Video transcript

The KEMRI Wellcome Trust Research Programme is based in Kenya under the Ministry of Health, and brings together leading scientists from Kenya, from Africa and from around the world. Our work has contributed to improved health through the development and evaluation of ways to treat and prevent diseases like malaria, yellow fever, pneumonia and Ebola.

KEMRI’s research is informed and supported by community and stakeholder engagement. This engagement, combined with meeting National and international guidelines, ensures that our work meets the highest ethical standards.

Given the current COVID-19 pandemic, it is essential that Kenyan researchers play a prominent role in addressing one of the greatest health challenges of our time. Kenyan researchers from KEMRI-Wellcome Trust Research Programme are currently collaborating with researchers from the UK to evaluate a new vaccine called ChAdOx1 nCoV-19.

So how will this vaccine work and how will researchers evaluate it to see if it gives protection?

People who have never had COVID-19 can easily become infected themselves if they come into close contact with a person who has the disease. This is because they have no natural immunity, or defence to protect them against infection. Being infected may enable the body to build natural immunity which may prevent a second infection. Vaccines mimic this. When a person is vaccinated, the vaccine stimulates the body to produce an immune response, or a defence against infection.

A tremendous amount of lab work is needed to develop a vaccine and this can take many years.  From the initial lab work, trial vaccines are first tested on animals, and if safe, they proceed through different stages of clinical trials with people. Initially, trials with relatively small numbers of volunteers are done to see how the body’s defense responds to the vaccine and to confirm the vaccine’s safety. Then trials are done with larger numbers of volunteers to see whether they give protection against disease. When there is strong, carefully reviewed evidence of protection, regulatory bodies give permission for the vaccines to be rolled out to large populations, but the vaccines are still monitored. The whole process of developing and evaluating a vaccine can take many years

Before any health research can be done with people in Kenya, the research must be carefully reviewed and approved by local, national and international scientific and ethical committees. These committees check that the scientific plan is strong, that the risks to participants are minimized and that their rights are guarded.

So let’s have a closer look at how the new ChAdOx1 trial vaccine is made.

This is a picture of an Adenovirus, which causes a mild flu amongst chimpanzees. It can be used to deliver the vaccine into the human body, but first, the adenovirus is modified so that it cannot cause any disease in humans.

Then, researchers carefully extract a component of genetic material from a COVID-19 virus and insert it into the genetic material of the adenovirus. This specific component stimulates the human body’s immune response. More of this modified adenovirus is made so that a vaccine can be prepared.

A similar approach was used to make the Ebola vaccines that controlled the epidemic in West Africa. The approach is also used in development of vaccines for other diseases of public health importance in Africa and Europe.

We want to find out whether this approach can be used in the new vaccine to protect people from COVID-19 infection. To do this, researchers need to compare the group receiving the ChAdOx1 trial vaccine, with a control group. Control groups enable researchers to compare how well the vaccine works against a substance which does not offer any protection at all against covid-19. In this trial, rabies vaccine is used as a control.  We know that rabies vaccine doesn’t protect against COVID-19, but it will give participants protection against Rabies… as a benefit for taking part in the trial.

Forty volunteers will take part in the trial for the first month. This will enable researchers to confirm the safety of ChAdOx1. The study will be explained to them, and if they are healthy and willing to participate, they will sign a consent form. Each of 40 participants is given either the ChAdOx1 vaccine, or the control - in this case rabies - and this is decided randomly, or by chance, a bit like flipping a coin. But, participants will not know whether they have been given the ChAdOx1 vaccine, or whether they were given the control. This is to make sure that their behaviour is not influenced by the type of vaccine given to them.

Participants will be followed-up to closely monitor:

  • Their health,
  • The safety of the vaccine and whether participants experience vaccine reactions like mild fever, swelling or itchiness around the site of the injection,
  • And how the participants bodies develop immunity in response to the vaccine

Because of the way it’s made, the vaccine can’t cause COVID-19 infection, but If a participant becomes infected through contact with an infected person in the community, then they will be treated according to the Ministry of Health guidelines. They will also be reminded to try to avoid infection through following government guidelines on hand-washing and social distancing.

When researchers are confident that the research can proceed, 360 new participants will be recruited. Again, chance will be used to decide which vaccine participants are given. Half the participants will be given ChAdOx1 and the other half will receive the control. Over the next 12 months, all the participants including the initial 40 volunteers, will be monitored and checked regularly. As new infections inevitably occur, researchers will be able to see whether the trial vaccine ChAdOx1 gives better protection than the control.

Collaboration between research institutions across the world is essential to develop and assess globally acceptable health innovations, and Kenyan researchers are at the forefront of collaborative efforts to develop and evaluate a vaccine which may offer protection from COVID-19.

Similar stories

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

@Oxford Research

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

@Oxford MORU Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Receiving and responding to community feedback during health system crises in Kenya

KWTRP Publication Research

The responsiveness of a health system is one of its goals, alongside fairness in financing and outcomes. Listening and responding to the public can make a health system stronger and fairer. However, responsiveness is likely to be undermined, especially for vulnerable and marginal populations, in periods of crises such as disease outbreaks. In the current COVID-19 crisis, there has been more focus on health system control interventions, with minimal consideration of community views. KWTRP colleagues in Kenya consider community engagement and citizens feedback channels, concerns raised by the public and how they were handled, and highlight lessons learned.

RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19

@Oxford Research

Established in March 2020, the RECOVERY trial tests a range of potential treatments for COVID-19, including azithromycin, a widely used antibiotic that also reduces inflammation. The azithromycin arm of the trial was established to determine whether or not the drug has a meaningful benefit among patients hospitalised with COVID-19. A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality; there was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.

Knowledge brokering platform launched to support health systems in the African region

KWTRP

The World Health Organization and partners including the KEMRI Wellcome Trust Research Programme launched AHOP (African Health Observatory Platform), an online platform to promote the exchange of evidence and experience across countries in the African region. By working to foster evidence-informed decision-making in an endeavor to re-engineer health service delivery, the initiative is expected to drive countries’ health system resilience efforts.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

@Oxford MORU Publication Research

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.